April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Disease Recurrence Not Significantly Delayed With Panvac Plus BCG in Advanced NMIBC
September 13th 2021n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.
Read More
Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 13th 2021Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.
Read More
Aveluamab With BCG Induction Shows Early Safety/Tolerability in BCG-Unresponsive NMIBC
September 13th 2021Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Read More
N-803 in Combination With BCG Yields Encouraging Responses in BCG-Unresponsive Bladder Cancer
September 10th 2021Patients with BCG-unresponsive, non-muscle invasive bladder cance carcinoma in situ had promising responses to Bacille Calmette-Guérinplus N-803, updated data from cohort A of the phase 2/3 QUILT-3.032 study.
Read More
Elevated Antibody Titers May Be a Prognostic Marker in BCG-Unresponsive NMIBC
September 10th 2021According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.
Read More
Buparlisib Treatment Begins in Combination With AN0025 and Atezolizumab for Advanced Solid Tumors
September 9th 2021The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.
Read More
Study Explores Sacituzumab Goveitecan Versus SOC in Metastatic or Locally Advanced Unresectable UC
August 30th 2021Sacituzumab goveitecan has been administered to the first time in a patient with metastatic or locally advanced unresectable urothelial carcinoma as part of the phase TROPICS-04 study.
Read More
FDA Approves Adjuvant Nivolumab for Surgically Resected, High-Risk Bladder Cancer
August 20th 2021The FDA has granted approval to nivolumab as an adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
Read More
MRD Assay Is New Step in Urothelial Cancer Testing
August 13th 2021A post hoc analysis from the IMvigor010 study evaluating circulating tumor ctDNA in patients receiving adjuvant atezolizumab in high-risk muscle-invasive urothelial cancer after surgery was presented at the European Society of Medical Oncology Immuno-Oncology Virtual Congress in 2020.
Read More
Low-Dose Chemotherapy With Immunotherapy Shows Efficacy in UC
August 3rd 2021In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC.
Read More